How to Sell a Dialysis Business (2026): Multiples, Buyer Pool, & Operator Playbook
Quick Answer
Christoph Totter · Managing Partner, CT Acquisitions
M&A advisory across 500+ active capital partners · Healthcare services M&A: dialysis, nephrology, MSO · Updated June 6, 2026
A US dialysis center business in 2026 typically sells for roughly 5x to 11x EBITDA. The US dialysis market is extremely consolidated, DaVita Inc. (NYSE: DVA, ~3,000 centers) and Fresenius Medical Care (NYSE: FMS, ~2,600 US centers) together own approximately 80% of US dialysis centers. The buyer pool for independent dialysis centers is narrow but real, with the two giants plus US Renal Care (Bain Capital + Goldman Sachs + Leonard Green Partners), Innovative Renal Care (Nautic Partners), and Satellite Healthcare (non-profit) as the named acquirers. By profile: a single dialysis center with low census (60-100 patients) goes 5x-7x EBITDA; a multi-center independent group (2-5 centers, $1.5-4M EBITDA) goes 6x-8x; a regional independent platform (5-15 centers, $4-12M EBITDA) goes 7x-9x; a premium scale platform ($12M+ EBITDA, multi-state, integrated home dialysis, value-based kidney care positioning) reaches 8x-11x+ EBITDA. Active buyers include DaVita Inc. (NYSE: DVA, ~$12B+ revenue, the largest US dialysis provider), Fresenius Medical Care (NYSE: FMS, ~$20B+ global revenue), US Renal Care (PE-backed by Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners, the third-largest US dialysis provider), Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit, the largest US non-profit dialysis provider), Strive Health (value-based kidney care, Town Hall Ventures + CapitalG/Google), Dialyze Direct (PE-backed, home dialysis focus), American Renal Associates (DaVita subsidiary post 2021 acquisition), Centers for Dialysis Care (PE-backed regional). The biggest multiple drivers are patient census per center (60-100+ census per center is operating-benchmark), modality mix (home dialysis – HHD/PD – is the growth premium driven by CMS), value-based kidney care positioning (KCC, KCF, ETC models), water-treatment compliance, CMS Star ratings, and Medicare ESRD population served. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.
If you own a dialysis center or independent dialysis group in 2026, the M&A market is concentrated. DaVita Inc. (NYSE: DVA) and Fresenius Medical Care (NYSE: FMS) together own approximately 80% of US dialysis centers, making this one of the most consolidated healthcare verticals. US Renal Care (Bain Capital + Goldman Sachs + Leonard Green Partners) is the third-largest with several hundred centers. Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit), and Strive Health (value-based kidney care) are other named participants. The market dynamics are shifting toward home dialysis (HHD + PD) and value-based kidney care models, which is creating new acquirer interest.
What the asset is worth depends on three things: (1) patient census per center (60-100+ is the operating-benchmark), (2) modality mix (home dialysis premium driven by CMS ETC and KCC value-based models), and (3) regulatory and compliance posture (water-treatment, CMS Star ratings, ESRD QIP performance). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Dialysis multiples 2026: 5x-7x for single-center low-census, 6x-8x for multi-center independent, 7x-9x for regional platforms, 8x-11x+ for premium scale with home dialysis + value-based kidney care positioning.
- Active buyers (narrow but real): DaVita Inc. (NYSE: DVA, ~3,000 centers, ~$12B+ revenue), Fresenius Medical Care (NYSE: FMS, ~2,600 US centers, ~$20B+ global revenue), US Renal Care (Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners), Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit), Strive Health (Town Hall Ventures + CapitalG/Google), Dialyze Direct.
- Market structure: DaVita + Fresenius own ~80% of US dialysis centers. Independent and PE-backed platforms compete for the remaining ~20%.
- PE sponsor activity: Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners (US Renal Care), Nautic Partners (Innovative Renal Care), Town Hall Ventures + CapitalG (Strive Health), plus multiple healthcare-services PE funds.
- Multiple drivers: patient census per center, modality mix (home dialysis HHD/PD growth premium driven by CMS ETC/KCC value-based models), value-based kidney care positioning, water-treatment compliance, CMS Star ratings, ESRD QIP performance, Medicare ESRD population.
- Things that compress the multiple: low census per center, hemodialysis-only without home modalities, weak CMS Star ratings, water-treatment compliance issues, no value-based kidney care positioning, single-payer concentration, single-state without expansion path.
- No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.
Named dialysis M&A transactions (2021-2025)
CT Acquisitions · 2026 Buyer-Market Signal
What Dialysis Buyers Underwrite in 2026
Across our buy-side conversations with dialysis acquirers in 2026:
- The duopoly distorts buyer-pool math. DaVita + Fresenius own ~80% of US centers, so independent operators sell to remaining buyers (US Renal Care, Innovative Renal Care) or regional PE-backed nephrology.
- Medical director relationships are integration risk. Independent operators with embedded local-nephrologist relationships face buyer concerns about post-close MD transition.
- CON state status affects multiples. Certificate-of-Need state operators command premium because regulatory moat caps new-build competition.
Multiple at a Glance · 2026
Dialysis Business Sale Multiples · 2026
By operator scale.
Source: CT Acquisitions analysis of dialysis M&A. DaVita (~3,000 centers) and Fresenius (~2,600 US) own ~80%; US Renal Care, Innovative Renal Care + regional PE acquire remaining 20%.
Related Cluster GuideFor the broader medical-practice sale playbook on how to sell a medical practice, see our companion reference.
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| American Renal Associates | DaVita Inc. (NYSE: DVA) | 2021 | Major US dialysis consolidation; DaVita acquired the third-largest US dialysis provider. |
| Strive Health funding rounds | Town Hall Ventures + CapitalG (Google) + others | 2022-2024 | Value-based kidney care platform raised substantial venture funding; new subsegment validation. |
| US Renal Care continued growth | Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners | 2022-2025 | PE-backed third-largest US dialysis provider continues regional rollups. |
| Innovative Renal Care expansion | Nautic Partners | 2022-2025 | PE-backed dialysis platform continues regional rollups. |
| CMS ETC and KCC model rollouts | CMS (regulatory) | 2022-2025 | End-Stage Renal Disease Treatment Choices (ETC) + Kidney Care Choices (KCC) value-based models reshape industry economics. |
| Multiple regional center tuck-ins | DaVita + Fresenius + US Renal Care | 2022-2025 | The three largest dialysis providers continue regional center acquisitions where local market allows. |
The named buyer landscape
The Big Two (own ~80% of US dialysis centers)
- DaVita Inc. (NYSE: DVA, ~$12B+ revenue), ~3,000 US centers, the largest US dialysis provider. Acquired American Renal Associates in 2021.
- Fresenius Medical Care (NYSE: FMS, ~$20B+ global revenue, ~$14B+ US), ~2,600 US centers, second-largest. German parent company.
Third-tier PE-backed and large independent
- US Renal Care (Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners), ~$2B+ revenue, third-largest US dialysis provider.
- Innovative Renal Care (Nautic Partners), PE-backed regional platform.
- Satellite Healthcare (non-profit), the largest US non-profit dialysis provider.
Value-based kidney care and home-dialysis platforms
- Strive Health (Town Hall Ventures + CapitalG / Google), value-based kidney care platform.
- Dialyze Direct (PE-backed), home dialysis focus.
- Centers for Dialysis Care (PE-backed), regional.
PE sponsors active in this space
- Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners (US Renal Care), Nautic Partners (Innovative Renal Care), Town Hall Ventures + CapitalG / Google (Strive Health), plus multiple healthcare-services PE funds.
What each buyer will pay for vs. what they reject
- Will pay premium for: patient census per center (60-100+ census), modality mix with home dialysis (HHD home hemodialysis + PD peritoneal dialysis) capability, value-based kidney care model participation (CMS ETC End-Stage Renal Disease Treatment Choices, KCC Kidney Care Choices, KCF Kidney Care First), water-treatment compliance with state and CMS standards, CMS Star ratings (4+ stars is premium), ESRD QIP (Quality Incentive Program) high performance, named commercial in-network contracts, modern operating system.
- Will compress or reject: low census per center, hemodialysis-only without home modalities, weak CMS Star ratings (1-2 stars), water-treatment compliance issues, no value-based kidney care positioning, single-payer concentration, single-state without expansion path, open CMS or state-health-department survey findings.
The operator-level KPI playbook buyers will diligence
Census and modality
- Patient census per center: 60-100+ census is the operating benchmark.
- Modality mix: In-center hemodialysis (ICHD) %, home hemodialysis (HHD) %, peritoneal dialysis (PD) %.
- Home dialysis percentage: CMS targets 80% home dialysis or transplant; premium platforms are growing home modalities.
- Treatment volume per chair per day.
- Census growth rate.
Payer mix
- Medicare percentage: ESRD population is heavily Medicare (~85-90% typical).
- Commercial percentage: Pre-ESRD commercial coverage and Medicare-Advantage ESRD growth.
- Medicaid percentage.
- Workers’-comp / auto / other commercial.
- 21st Century Cures Act MA enrollment dynamics.
Value-based kidney care
- CMS ETC (End-Stage Renal Disease Treatment Choices) participation: Mandatory model in some HRRs; document.
- CMS KCC (Kidney Care Choices) participation: Voluntary value-based models.
- CKCC entity affiliations: Comprehensive Kidney Care Contracting entities.
- Performance metrics: Reduced hospitalizations, increased home modality, increased transplant.
Regulatory and quality
- CMS Five-Star ratings: 1-5 stars on the CMS Care Compare site.
- ESRD QIP (Quality Incentive Program) score: Annual score affects reimbursement; track historical.
- State health department survey history.
- Water-treatment compliance: AAMI standards, documented water-quality monitoring.
- Vascular access management: AVF vs. AVG vs. catheter percentage; AVF is the quality benchmark.
- Infection control (HAIs): Bloodstream infection rates.
Operating system and technology
- Dialysis-specific EMR: Acumen Nephrology, BluePrint by Fresenius, Inscope, Crown Web (CMS reporting).
- Patient registry and care coordination.
- Treatment data integration with dialysis machines.
Workforce
- Medical director and nephrologist coverage.
- Dialysis nurse and technician headcount.
- Social worker and dietitian on staff.
- Staff turnover.
Dangers and traps in dialysis M&A
1. Market concentration limits buyer pool
DaVita + Fresenius own ~80% of US dialysis centers. The buyer pool for independents is narrow: the two giants, US Renal Care, Innovative Renal Care, Satellite Healthcare, and a handful of value-based platforms.
2. Low census per center
Below 60 patient census per center compresses the multiple materially. Premium platforms operate 80-120+ census per center.
3. Hemodialysis-only without home modalities
CMS is pushing home dialysis (HHD + PD) via ETC and KCC value-based models. Hemodialysis-only operations face structural reimbursement pressure.
4. Weak CMS Star ratings or ESRD QIP performance
1-2 star ratings or low QIP scores signal quality issues and trigger reimbursement reductions.
5. Water-treatment compliance
Water-treatment failures (AAMI standards, microbial contamination) are deal-killers and create patient-safety liability.
6. Vascular access management
High catheter rate (vs. AVF/AVG) signals access management problems. CMS pushes AVF as the quality benchmark.
7. Single-payer or Medicare-Advantage exposure
21st Century Cures Act enabled MA enrollment for ESRD beneficiaries; track MA penetration carefully.
8. Open survey findings
State health department or CMS survey deficiencies must be resolved.
Our POV on dialysis M&A in 2026
Dialysis is the most consolidated healthcare-services vertical: DaVita + Fresenius own ~80% of US dialysis centers. Buyer pool for independents is narrow but real, dominated by the Big Two plus US Renal Care (Bain Capital + Goldman Sachs + Leonard Green), Innovative Renal Care (Nautic Partners), and value-based kidney care platforms (Strive Health). Multiples are mid-to-high single digits for the right asset, with premium for home dialysis modalities and value-based kidney care positioning.
Preparing your dialysis business for sale: 12-18 months out
- Get multi-year audited financials. Document census growth, modality mix, payer mix.
- Build home dialysis capability. HHD and PD modalities; document growth trajectory.
- Document CMS ETC + KCC value-based participation.
- Improve CMS Star ratings and ESRD QIP performance.
- Confirm water-treatment compliance. AAMI standards, microbial monitoring.
- Improve vascular access management. AVF percentage above catheter benchmark.
- Resolve any state survey or CMS findings.
- Modernize the operating system. Dialysis-specific EMR.
- Run a competitive process. DaVita Inc. (NYSE: DVA), Fresenius Medical Care (NYSE: FMS), US Renal Care, Innovative Renal Care, Satellite Healthcare, Strive Health, plus PE sponsors directly (Bain Capital + Goldman Sachs + Leonard Green, Nautic Partners, Town Hall Ventures + CapitalG).
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Sell side for owners, buy side for acquirers, plus exit planning.
No fee on buy-side introductions. Sell side paid on success.
Search funders, family offices, lower-middle-market PE, strategics.
Introductions to the right buyers only. No public listing.
You see exactly how we are paid before any work starts.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next steps could look like. Terms are agreed in writing before any work starts.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for a dialysis business in 2026?
Single-center low-census dialysis (60-100 patients) typically sells at 5x-7x EBITDA. Multi-center independent groups (2-5 centers, $1.5-4M EBITDA) go 6x-8x. Regional independent platforms (5-15 centers, $4-12M EBITDA) go 7x-9x. Premium scale platforms ($12M+ EBITDA, multi-state, integrated home dialysis, value-based kidney care positioning) reach 8x-11x+.
Who are the active buyers of dialysis businesses right now?
The Big Two own ~80% of US dialysis centers: DaVita Inc. (NYSE: DVA, ~3,000 centers, ~$12B+ revenue) and Fresenius Medical Care (NYSE: FMS, ~2,600 US centers, ~$20B+ global revenue). Third-tier: US Renal Care (PE-backed by Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners, ~$2B+ revenue), Innovative Renal Care (Nautic Partners), Satellite Healthcare (non-profit). Value-based: Strive Health (Town Hall Ventures + CapitalG/Google), Dialyze Direct (home dialysis). PE sponsors: Bain Capital + Goldman Sachs Asset Management + Leonard Green Partners, Nautic Partners, Town Hall Ventures + CapitalG.
Why is dialysis M&A so concentrated?
DaVita and Fresenius spent two decades consolidating the US dialysis market. ESRD patients are predominantly Medicare-covered, which creates predictable revenue but caps margin. The economics favor scale (water treatment, supply purchasing, nephrologist contracting), and the Big Two have ~80% market share. The remaining ~20% is independent and PE-backed operators competing in regional markets.
What hurts a dialysis business’s valuation most?
Low patient census per center (below 60), hemodialysis-only without home modalities (CMS pushes home dialysis through ETC and KCC value-based models), weak CMS Star ratings (1-2 stars), water-treatment compliance failures, no value-based kidney care positioning, single-state operations without expansion path, single-payer concentration, and open state health department or CMS survey findings.
What are CMS ETC and KCC value-based kidney care models?
ETC (End-Stage Renal Disease Treatment Choices) is a CMS mandatory model in selected Hospital Referral Regions (HRRs) that incentivizes home dialysis (HHD + PD) and transplant. KCC (Kidney Care Choices) is a voluntary CMS value-based model with multiple tracks (KCF Kidney Care First, CKCC Comprehensive Kidney Care Contracting) where participating providers take on financial risk for total cost of care for ESRD and late-stage CKD patients. Premium dialysis platforms increasingly position around these value-based models.
Do I have to pay a broker fee?
It depends on the mandate. CT Strategic Partners works both sides of the table and is not a business broker. When a buyer from our network approaches you through a buy-side search, you pay no fee; when you hire us to run a sell-side process, we are paid on success at closing, with terms agreed in writing before any work starts.
How long does it take to sell a dialysis business?
Once you go to market with an M&A advisor, a typical process runs 6-9 months from initial outreach to closing, with regulatory diligence extending the timeline. Add 12-18 months of preparation work before going to market.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market is the right window. Highest-leverage pre-sale work: build home dialysis (HHD + PD) capability, participate in CMS ETC/KCC value-based models, improve CMS Star ratings and ESRD QIP performance, confirm water-treatment compliance, and document census growth.
Related research
- How to sell an infusion therapy business
- How to sell a specialty pharmacy
- How to sell a home health agency
- How to sell a hospice business
- How to sell a clinical laboratory
- How to sell an imaging center
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Private equity value creation
- Business broker alternative
About the Author
Broker fees carry a real drag on net proceeds. See our full broker economics for sellers for the numbers.
Christoph Totter is the founder of CT Acquisitions, an M&A advisory firm working both sides of the table, headquartered in Sheridan, Wyoming. We work directly with 500+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. Connect on LinkedIn · Get in touch
